RNA, U4 small nuclear 68, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-68P profile across patient tissues and cancer cell-line models. RNU4-68P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RNU4-68P is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, RNU4-68P RNA expression shows 6,014 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, KIRC, and STAD as cancer lineages where RNU4-68P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-68P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-68P survival associations across molecular data types. RNU4-68P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-68P RNA expression–survival associations across cancer types. High RNU4-68P expression shows unfavorable associations in LUSC, UCEC, THYM, MESO and KIRC, but favorable associations in OV. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify LUSC as the clearest survival context for RNU4-68P RNA expression.
This table summarizes RNU4-68P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-68P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-68P shows lower tumor expression in KIRC. The KIRC box plot shows higher RNU4-68P RNA expression in normal versus tumor tissue (log2 FC = −0.060, t-test p = .004).
This table shows molecular features associated with RNU4-68P in patient tissues and cancer cell lines. In patient samples, RNU4-68P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
